Dr Jacqualyn Fouse, president and chief operating officer of Celgene, is set to retire from 1 April, remaining a strategic advisor to the management team until 30 June 2017.
Scott Smith has been named as Dr Fouse’s successor, and the company has promoted Terrie Curran to take his place as president of its global inflammation and immunology (I&I) franchise.
Dr Fouse (pictured right) joined Celgene in 2010 as chief financial officer, and was appointed president of its haematology and oncology franchise four years later. She took on her current roles in March 2016, having been elected to Celgene’s board of directors the previous month.
Previously, Dr Fouse was chief financial officer of agribusiness and food company Bunge, and also brought executive leadership expertise from Alcon Laboratories and Nestlé.
Mark Alles, chief executive officer at Celgene, said: “I would like to thank Jackie for her incredible commitment and dedication to Celgene and the patients we seek to serve worldwide.
“On behalf of all Celgene employees, I wish Jackie the best in her retirement.”
Meanwhile, Smith (pictured left) joined Celgene in 2008 to launch the firm’s I&I franchise, serving first as vice president for global marketing before his promotion to senior vice president and global head of the franchise.
Smith has over 30 years of business strategy experience across a range of therapeutic areas, having previously held senior leadership roles at Biovail in Canada, France, the US and Hong Kong, as well as sales positions at Pfizer’s Pharmacia.
Alles said: “Scott is a tremendous leader with extensive industry experience and his teams have consistently delivered outstanding results.
“Our organisation will benefit from Scott’s business expertise, strategic leadership, and focus on operational excellence.”
Smith’s successor, Curran, joined Celgene in 2013 as the US commercial head of the I&I franchise, and was promoted to head of worldwide commercial markets for I&I last year.
Her previous experience includes serving as a senior vice president at Merck & Co, where she led the global women’s health franchise from 2009 to 2013.
Alles added: “Terrie has been instrumental in establishing Celgene as a leader in the inflammation and immunology marketplace.
“Terrie’s knowledge of our business and strategic capabilities will greatly benefit Celgene as we continue to build a preeminent global inflammation and immunology franchise.”